-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral

Benzinga·05/22/2026 10:41:16
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Neutral.